Trial Profile
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 Apr 2020 Planned End Date changed from 31 Dec 2019 to 1 Aug 2020.
- 23 Apr 2020 Planned primary completion date changed from 31 Jan 2019 to 1 Aug 2020.
- 04 Jun 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).